期刊
ARCHIVES OF DERMATOLOGICAL RESEARCH
卷 311, 期 1, 页码 29-36出版社
SPRINGER
DOI: 10.1007/s00403-018-1876-y
关键词
Alopecia areata; Apremilast; PDE4 inhibitor; Placebo-controlled trial; Moderate-to-severe AA
类别
资金
- Celgene [AP-CL-ALOP-PI-005776]
Alopecia areata (AA) is a common autoimmune disease that results in non-scarring hair loss. AA pathogenesis is thought to involve multiple inflammatory cytokines. Apremilast is a phosphodiesterase 4 (PDE4) inhibitor that reduces pro-inflammatory cytokine production. Recent studies demonstrate upregulation of PDE4 in human scalp lesions of AA patients and hair regrowth in a humanized AA mouse model upon apremilast treatment, suggesting a possible potential of apremilast in AA. To assess the efficacy and safety of apremilast in AA, we conducted a double-blind, placebo-controlled single-center pilot study in 30 moderate-to-severe AA patients (50% scalp involvement) that were randomized 2:1 to receive apremilast (n=20) or placebo (n=10) orally for 24weeks. The primary endpoint was the percentage of patients achieving 50% reduction in severity of alopecia tool (SALT) score (SALT(50)) at 24weeks compared to baseline, and the secondary endpoints included the percent change in SALT score at weeks 24 and 48. Eight patients in the apremilast arm withdrew prior to week 24 along with two patients in the placebo group, mostly due to lack of efficacy and adverse events. At 24weeks, only 1 of 12 apremilast-treated subjects achieved SALT(50), and similarly 1 of 8 placebo-treated subjects achieved SALT(50). The difference between the mean percent improvement in SALT score at week 24 compared to baseline of the two study arms was not statistically significant (p=0.38). The lack of treatment response in most of our patients argues against a pathogenic role for PDE4 specifically in moderate-to-severe AA, but targeting this pathway may still be of value in patients with mild AA as there is less of an inflammatory burden in this population. However, future larger studies may be needed to conclude apremilast's lack of efficacy in moderate-to-severe AA.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据